Organisation paid for research Program year 2022 Source: CMS Open Payments

Breakthrough Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$220,922

28 payments

Through program year 2022, Breakthrough Clinical Trials LLC is reported as receiving $220,922 in research payments, across 28 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $12,850 7
2020 Research $64,263 5
2019 Research $143,810 16

Breakdown

Who paid Research payments · program years 2019–2022
  1. Neurocrine Biosciences, Inc. $186,572 15 payments
  2. Allergan Inc. $21,500 6 payments
  3. Sage Therapeutics, Inc. $12,850 7 payments
Studies the money was for Research payments · program years 2019–2022
  1. The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine $93,691 5 payments
  2. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine $41,091 2 payments
  3. Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $28,618 5 payments
  4. A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $23,172 3 payments
  5. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $12,850 7 payments
  6. A 52-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active- Controlled, Operationally Seamless Phase 2B3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohns Disease $11,750 3 payments
  7. A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $9,750 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record